Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study-Reference-Cited by-同舟云学术

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Published:2021-10 Issue:5 Volume:6 Page:100270
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Bordonaro R.,Calvo A.,Auriemma A.,Hollebecque A.,Rubovszky G.,Saunders M.P.,Pápai Z.,Prager G.,Stein A.,André T.,Argilés G.,Cubillo A.,Dahan L.,Edeline J.,Leger C.,Cattan V.,Fougeray R.,Amellal N.,Tabernero J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Pharmacologic resistance in colorectal cancer: a review;Hammond;Ther Adv Med Oncol,2016

2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

3. Immunotherapy in colorectal cancer: available clinical evidence, challenges and novel approaches;Tintelnot;World J Gastroenterol,2019

4. TAS-102, a novel antitumor agent: a review of the mechanism of action;Lenz;Cancer Treat Rev,2015

5. Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages;Limagne;Cancer Immunol Res,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial;Digestive and Liver Disease;2024-08

2. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?;Current Oncology Reports;2024-07-30

3. Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment;Frontiers in Immunology;2023-09-18

4. Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients;BMC Immunology;2023-09-01

5. Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast Cancer;Journal of Translational Medicine;2022-10-20